Tectonic Therapeutic (NASDAQ:TECX - Get Free Report)'s share price reached a new 52-week high during trading on Thursday . The stock traded as high as $55.80 and last traded at $50.34, with a volume of 2556003 shares traded. The stock had previously closed at $25.72.
Analyst Upgrades and Downgrades
A number of analysts have weighed in on TECX shares. Raymond James began coverage on Tectonic Therapeutic in a research report on Wednesday, November 20th. They issued an "outperform" rating and a $65.00 price target on the stock. Leerink Partners increased their target price on shares of Tectonic Therapeutic from $49.00 to $69.00 and gave the stock an "outperform" rating in a research report on Monday, November 11th. Finally, Wells Fargo & Company lifted their price target on shares of Tectonic Therapeutic from $79.00 to $112.00 and gave the company an "overweight" rating in a report on Friday. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, Tectonic Therapeutic presently has a consensus rating of "Buy" and an average price target of $80.50.
Read Our Latest Research Report on TECX
Tectonic Therapeutic Price Performance
The stock has a 50 day moving average price of $45.64 and a two-hundred day moving average price of $33.64. The company has a market capitalization of $746.50 million, a price-to-earnings ratio of -8.59 and a beta of 2.62.
Tectonic Therapeutic (NASDAQ:TECX - Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($1.20) earnings per share for the quarter, missing the consensus estimate of ($0.84) by ($0.36). Sell-side analysts forecast that Tectonic Therapeutic will post -8.31 EPS for the current fiscal year.
Institutional Inflows and Outflows
Large investors have recently bought and sold shares of the company. Nordwand Advisors LLC acquired a new stake in shares of Tectonic Therapeutic during the 3rd quarter worth approximately $45,000. China Universal Asset Management Co. Ltd. acquired a new stake in Tectonic Therapeutic during the 4th quarter worth $144,000. Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Tectonic Therapeutic during the 3rd quarter valued at $233,000. Acuta Capital Partners LLC bought a new stake in shares of Tectonic Therapeutic during the 3rd quarter valued at $415,000. Finally, Clarius Group LLC acquired a new position in shares of Tectonic Therapeutic in the 4th quarter valued at $468,000. Institutional investors and hedge funds own 62.63% of the company's stock.
About Tectonic Therapeutic
(
Get Free Report)
Avrobio, Inc is a bio-technology company. It develops step-change cell and gene therapies for the treatment of cancer and rare disease. The company operates primarily in the United States and Canada. Avrobio, Inc is based in MA, United States.
Recommended Stories
Before you consider Tectonic Therapeutic, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tectonic Therapeutic wasn't on the list.
While Tectonic Therapeutic currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
